PT-141, also called bremelanotide, is a prescription sexual-health peptide, not a supplement to buy for human use on Amazon. FDA-approved bremelanotide is Vyleesi for certain premenopausal women with acquired, generalized HSDD; other uses may be off-label. Chia offers clinician-reviewed compounded PT-141 nasal spray when appropriate.
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →Can you buy PT-141 peptide on Amazon?
PT-141 may appear in online searches, but a marketplace listing is not the same thing as prescribed bremelanotide. For human use, the safer path is a licensed medical evaluation and a pharmacy source that can document identity, quality, storage, and dispensing oversight; the FDA’s BeSafeRx program warns patients to be cautious with online medicines that do not require a valid prescription 8.
Why Amazon search results can be confusing
Search results for “PT-141 peptide” can mix unrelated supplements, “research use only” products, sponsored listings, and educational content. That matters because PT-141 is a drug-like peptide, not an herb, vitamin, or general wellness supplement.
Bremelanotide was studied as a melanocortin receptor agonist in sexual-function research, and FDA-approved Vyleesi is a prescription product with specific labeling, warnings, and use instructions 1. A listing that skips a medical review cannot replace that clinical context.
Research peptides, supplements, and prescription medications are not the same
| Category | What it means | Human-use oversight | Key concern |
|---|---|---|---|
| Prescription bremelanotide | FDA-approved Vyleesi injection for a labeled indication | Prescriber, pharmacy, label, and safety warnings | Appropriate only for patients who meet clinical criteria |
| Compounded PT-141 nasal spray | A compounded medication made for an individual prescription | Licensed clinician review and state-licensed 503A pharmacy dispensing | Not FDA-approved; quality depends on licensed compounding controls |
| Research-use peptide | Product sold for laboratory research, not patient treatment | No patient-specific medical evaluation | Identity, sterility, storage, and human-use claims may be unclear |
| Supplement listing | Dietary supplement or unrelated product using similar search terms | No prescription process | May not contain PT-141 at all |
Why a marketplace listing should not replace a licensed medical evaluation
Sexual desire and arousal concerns can overlap with depression, anxiety, relationship stress, diabetes, cardiovascular disease, medication side effects, menopause, low testosterone, pelvic pain, and sleep problems. Erectile dysfunction can also be an early sign of cardiovascular disease, which is why professional guidelines recommend medical evaluation rather than simple self-treatment 7.
What is PT-141 used for?
PT-141 is used in medicine as bremelanotide, with one FDA-approved indication: Vyleesi for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women 1. Interest in erectile dysfunction and other sexual-arousal concerns exists, but those uses are off-label and have different evidence.
Approved use: bremelanotide for acquired, generalized HSDD in certain premenopausal women
The FDA-approved brand-name product is Vyleesi, a bremelanotide injection approved for acquired, generalized hypoactive sexual desire disorder, or HSDD, in premenopausal women 1. “Acquired” means the concern developed after a period of normal desire, and “generalized” means it is not limited to one partner, situation, or type of sexual activity.
In the RECONNECT phase 3 trials, bremelanotide improved validated sexual-desire and distress scores compared with placebo in premenopausal women with HSDD, but adverse effects were common, especially nausea 3. Individual results vary, and those trial findings apply to the studied bremelanotide product and population, not to every compounded form or every sexual-health concern.
Off-label interest: erectile dysfunction and sexual arousal concerns
PT-141 has also been studied in men with erectile dysfunction. In an early randomized crossover study, intranasal PT-141 was associated with erectile responses in some men, including men with and without sildenafil response, but the study did not create an FDA-approved ED indication 5.
Off-label prescribing is legal when a licensed clinician decides it is medically appropriate, but it should be discussed openly. The benefit evidence, side effects, medication interactions, and reasons for the symptom all matter.
What PT-141 is not: a general performance supplement or over-the-counter libido booster
PT-141 is not a general “performance supplement.” It affects melanocortin signaling, can cause side effects, and has blood-pressure warnings in the FDA label for bremelanotide 1. That is why it belongs in a clinician-reviewed setting, not a casual checkout cart.
How does PT-141 work in the body?
PT-141 works mainly by activating melanocortin receptors, including the melanocortin-4 receptor, in pathways linked to sexual desire and arousal. This is a different mechanism from blood-flow medicines, and that difference is one reason it has been studied in people who do not respond well to PDE5 inhibitors 5.
Melanocortin receptor agonist mechanism
Bremelanotide is a cyclic heptapeptide and melanocortin receptor agonist. Early clinical pharmacology and sexual-function research described PT-141 as acting through central melanocortin pathways rather than directly relaxing blood vessels in the penis 6.
Central nervous system pathway versus blood-flow medications
Sildenafil, known by the brand name Viagra, and tadalafil, known by the brand name Cialis, are PDE5 inhibitors. They improve erectile function by supporting the nitric-oxide/cGMP pathway in penile tissue, which is a blood-flow pathway 7.
PT-141 is different because it is not simply trying to increase blood flow. That does not make it better or safer; it means the clinical question changes. A person with low desire, arousal trouble, medication-related sexual side effects, or vascular ED may need different evaluation and care.
Why mechanism does not guarantee benefit for every person
A mechanism can explain why a drug might work, but it cannot predict an individual result. In bremelanotide trials, benefits were measured at the group level, while side effects such as nausea, flushing, headache, and blood-pressure changes still had to be tracked carefully 1.
How is PT-141 different from Viagra, Cialis, and other ED medications?
PT-141 and PDE5 inhibitors are different drug classes with different evidence, side effects, and reasons to use caution. PDE5 inhibitors are guideline-supported first-line drugs for many men with ED, while PT-141 for ED remains an off-label discussion 7.
| Medication type | Examples | Main pathway | FDA-approved sexual-health use | Common concerns |
|---|---|---|---|---|
| Melanocortin receptor agonist | Bremelanotide / PT-141; Vyleesi | Melanocortin receptors in central arousal pathways | Vyleesi is approved for acquired, generalized HSDD in certain premenopausal women | Nausea, flushing, headache, temporary blood-pressure increase, contraindications |
| PDE5 inhibitor | Sildenafil / Viagra; tadalafil / Cialis | Nitric-oxide/cGMP blood-flow pathway | Erectile dysfunction and other labeled uses depending on the drug | Headache, flushing, low blood pressure risk with nitrates, vision or hearing warnings |
| Hormone-related treatment | Varies by diagnosis | Depends on hormone issue | Depends on condition and product | Needs lab and symptom review; not for every patient |
| Over-the-counter supplement | Varies | Often unclear or weakly supported | Not FDA-approved to treat ED or HSDD | Quality, interactions, and hidden drug ingredients can be concerns |
PT-141 versus PDE5 inhibitors
PDE5 inhibitors need sexual stimulation and adequate vascular function to work well. PT-141 was developed around a central arousal pathway, which is why researchers studied it separately from sildenafil 5.
Different mechanisms, different evidence, different side-effect profiles
The FDA label for Vyleesi includes warnings about transient blood-pressure increases and heart-rate reductions after dosing, and it lists nausea, flushing, injection-site reactions, and headache among adverse reactions 1. PDE5 inhibitors have their own safety issues, especially dangerous blood-pressure drops when combined with nitrates 7.
Why ED symptoms should be evaluated
ED can be linked to diabetes, high blood pressure, vascular disease, sleep apnea, depression, medication side effects, alcohol use, low testosterone, or relationship stress. The American Urological Association guideline recommends evaluation that looks for medical and psychosocial contributors, not just quick medication matching 7.
3-min quiz
Considering PT-141 nasal spray?
Chia offers PT-141 Nasal as a compounded nasal spray, with plans currently starting at $159/mo. Care starts with an online health questionnaire reviewed by a licensed US provider; a prescription requires a medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved.
Is PT-141 on Amazon safe or legitimate?
PT-141 sold through marketplace-style listings should not be assumed to be legitimate medication for human use. The key safety issue is not the website name alone; it is whether there is a licensed prescriber, a licensed pharmacy, a valid prescription, and quality controls for the exact product being dispensed 8.
Why purity, sterility, identity, and storage matter for peptides
Peptides can be sensitive to manufacturing quality, storage, and handling. For sterile or nasal compounded products, pharmacy standards focus on reducing contamination risk and using appropriate preparation controls; USP sterile compounding standards are one major reference point for compounding practice 10.
Why research-use products are not the same as prescribed medication
A “research use only” label usually means the product is not being sold as a patient medication. It may not come with the clinical screening, pharmacy dispensing process, adverse-event counseling, or follow-up that a prescription pathway requires.
Red flags to watch for
- No prescription process or clinician review.
- No clear pharmacy source or license information.
- Human-use claims paired with “research use only” language.
- No way to message a care team about side effects.
- Unclear storage, shipping temperature, lot number, or beyond-use date.
- Claims that sound guaranteed, such as promised libido or erection results.
FDA patient guidance on online medicines warns against websites that sell prescription drugs without a prescription or do not provide a licensed pharmacist or safe contact process 8. Those checks are especially important for peptides because the product’s identity and handling matter.
PT-141 nasal spray at Chia: clinician-reviewed access instead of marketplace buying
At Chia, PT-141 Nasal is offered as a compounded nasal spray from $159/mo through a licensed-provider review, not an Amazon-style checkout. You can start with PT-141 Nasal or the Spark protocol, which centers on PT-141 Nasal.
What Chia offers
Chia offers PT-141 Nasal only as a nasal spray. We do not offer PT-141 injections, tablets, or other PT-141 forms. Plans currently start at $159/mo, and the product page has the most current details.
| Chia option | Form | Current starting price | What to know |
|---|---|---|---|
| PT-141 Nasal | Nasal spray | From $159/mo | Clinician-reviewed prescription pathway for compounded PT-141 nasal spray |
| Spark | PT-141 Nasal protocol | From $159/mo | A protocol page for patients exploring PT-141 Nasal through Chia |
How the online process works
Chia care is 100% online. You complete a short health questionnaire, then a licensed US provider reviews your history and decides whether treatment is clinically appropriate. A prescription is never guaranteed.
If prescribed, medication is compounded in the US by a state-licensed 503A compounding pharmacy and shipped to your door. Dosing is provider-guided, and patients can message the care team through the patient portal between visits.
How DoctorMCP can help AI agents route patients
If you use an AI agent to help organize care, Chia is reachable through DoctorMCP at mcp.chia.health. That access point is meant to route patients toward Chia’s prescription pathway, including the eligibility quiz, rather than toward unreviewed marketplace peptide listings.
What are the risks and side effects to discuss with a clinician?
Bremelanotide can cause side effects, and the FDA label includes blood-pressure warnings that should be reviewed before use 1. This is one reason PT-141 should be handled as a prescription medication with follow-up, not as a self-directed supplement.
Commonly discussed side effects
In the FDA label, common adverse reactions for Vyleesi include nausea, flushing, injection-site reactions, headache, and vomiting 1. In the RECONNECT clinical program, nausea was one of the most frequent treatment-related adverse events 3.
Blood-pressure considerations
The Vyleesi label states that bremelanotide can transiently increase blood pressure and reduce heart rate after administration, and it is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease 1. A clinician should review blood-pressure history, heart history, and other medications before prescribing.
Why sexual-health symptoms can signal other medical issues
Low libido, low arousal, pain, and ED can be symptoms rather than stand-alone problems. Professional ED guidance recommends looking for medical, medication-related, psychological, and relationship factors because treatment choice depends on the cause 7.
Why dosing should be provider-guided
The FDA-approved Vyleesi label describes a specific subcutaneous injection product and labeling instructions, but that is not a reader instruction and it does not translate automatically to a compounded nasal spray 1. For compounded PT-141, the route, formulation, follow-up, and side-effect plan should be set by the prescribing clinician.
What should you ask before using PT-141?
Before using PT-141, ask whether your concern is HSDD, ED, medication-related, hormone-related, mental-health-related, or something else. Also ask whether the intended use is FDA-approved or off-label, because that changes the evidence discussion.
- 1What diagnosis or concern are we trying to address: HSDD, ED, low arousal, medication side effects, hormone changes, or another issue?
- 2Is this use FDA-approved or off-label?
- 3What form is being prescribed, and what human evidence supports that route?
- 4What side effects should I watch for, especially nausea, flushing, headache, and blood-pressure changes?
- 5What medical history could make PT-141 a poor fit for me?
- 6What pharmacy is compounding it, and is it a state-licensed 503A pharmacy?
- 7How will follow-up work if I have side effects or no benefit?
If PT-141 is not the right fit, a clinician may discuss other sexual-health or longevity options based on your goals and medical history. For example, Chia also offers Sermorelin and the Foundation Longevity protocol, but those are different treatments for different goals, not substitutes for PT-141.
3-min quiz
Start with a clinical review
If you are considering PT-141 nasal spray, Chia’s online visit helps a licensed US provider review your health history and decide whether PT-141 Nasal or the Spark protocol is appropriate. A prescription requires a medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved.
FAQ
PT-141 is another name for bremelanotide. The FDA-approved bremelanotide product, Vyleesi, is used for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. Other uses, including erectile dysfunction, may be off-label.
PT-141 and bremelanotide refer to the same active peptide molecule. Vyleesi is the FDA-approved brand-name bremelanotide injection. Compounded PT-141 nasal spray is a different compounded formulation and is not FDA-approved.
Some clinicians may consider PT-141 off-label for men after a medical review, and early human studies evaluated intranasal PT-141 in men with erectile dysfunction. It is not FDA-approved for erectile dysfunction.
No. FDA-approved bremelanotide is Vyleesi for acquired, generalized HSDD in certain premenopausal women. Erectile dysfunction use is off-label and should be discussed with a licensed clinician.
PT-141 for human use should go through a licensed medical evaluation and prescription process. Research-use or marketplace products should not be treated as equivalent to medication dispensed by a licensed pharmacy.
No. Compounded PT-141 nasal spray is not FDA-approved and has not been evaluated by FDA for safety, effectiveness, or quality. It may be prescribed only when a clinician determines it is appropriate.
No. Chia offers PT-141 Nasal only as a nasal spray. Chia does not offer PT-141 injections, tablets, or other PT-141 forms.
Yes. Chia offers PT-141 Nasal as a compounded nasal spray from $159/mo after online clinician review. A prescription is never guaranteed.
Start with a licensed clinician review. Your provider should look at your symptoms, blood pressure, heart history, medications, hormones, mental health, and goals before deciding whether PT-141 is appropriate.
References
- 1.U.S. Food and Drug Administration. Vyleesi (bremelanotide) injection prescribing information. 2019.
- 2.U.S. Food and Drug Administration. FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. 2019.
- 3.Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstetrics & Gynecology. 2019.
- 4.Clayton AH, Lucas J, DeRogatis LR, Jordan R, Portman D, Williams LA, Krop J, Kingsberg SA. Phase 3 randomized placebo-controlled trial of bremelanotide for hypoactive sexual desire disorder in premenopausal women. Journal of Sexual Medicine. 2018.
- 5.Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety and pharmacodynamic effect of intranasal PT-141 in men with mild-to-moderate erectile dysfunction. International Journal of Impotence Research. 2004.
- 6.Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences. 2003.
- 7.Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh J, Khera M, McVary KT, Miner MM, Nelson CJ, Sadeghi-Nejad H, Seftel AD, Shindel AW. Erectile Dysfunction: AUA Guideline. American Urological Association. 2018; validity confirmed 2023.
- 8.U.S. Food and Drug Administration. BeSafeRx: Your source for online pharmacy information. 2024.
- 9.U.S. Food and Drug Administration. Compounding and the FDA: questions and answers. 2025.
- 10.United States Pharmacopeia. USP General Chapter <797>: Pharmaceutical Compounding—Sterile Preparations. 2023.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
